Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Beam Therapeutics faces slow pipeline progress and high R&D costs despite a $500M cash boost. Learn why patience is key for ...

Q1 2025 Earnings Call Transcript May 27, 2025 BioLineRx Ltd. beats earnings expectations. Reported EPS is $1.39, expectations were $-0.84. Operator: Ladies and gentlemen, thank you for standing by.

Discover BioLineRx's Q1 2025 highlights, including APHEXDA growth, cost reductions, pipeline expansion, and updates on oncology trials.

The death of a patient in a trial of an experimental gene therapy casts new shadows over a technology once seen as the future ...